top of page
Multiple Myeloma Clinical Trials Currently Recruiting
2022 - (R) NCT05308654
Phase 1: A Study to Assess activity & AEs in RRMM Receiving Oral ABBV-453 Tablets
2022 - (R) NCT05288062
Phase 2: Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) + Dex
2022 - (R) NCT05227144
Phase 1: Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
2021 - (R) NCT05083169
Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - MajesTEC-3
2021 - (R) NCT05024045
Phase 1 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
2021 - (R) NCT04942067
Phase 1/2: APG-2575 in Combination With Novel Therapeutic Regimens in RRMM Myeloma
2021 - (R) NCT04855136
Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations in MM (KarMMa-7)
2021 - (R) NCT04776018
Phase 1/2: A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In RRMM
2021 - (R) NCT04764942
Phase 1/2: Selinexor, Pom, Dex +/- Carfilzomib RRMM Multiple Myeloma, The SCOPE Trial
2021 - (R) NCT04756726
Phase 1/2: CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
2021 - (R) NCT04398745
Phase 1: Belantamab Mafodotin With Normal and Varying Degree of Impaired Renal Function
2020 - (R) NCT04445701
Phase 1/2: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dex RRMM
NDMM
2022 - (R) NCT05288062
Phase 2: Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) + Dex
2021 - (R) NCT04923893
Phase 3 - Bort/Len/Dex f/b Cilta-cel f/b Len/Dex NDMM- ( No ASCT planned ) CARTITUDE-5
2020 - (R) NCT04566328
Phase 3 - Testing the Use of Combination Therapy in NDMM, the EQUATE Trial - EAA181
2020 - (R) NCT04268498
Phase 2 - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma (ADVANCE)
2019 - (R) NCT04071457
Phase 3: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maint. NDMM DRAMMATIC
2019 - (R) NCT03989414
Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002
2019 - (R) NCT03941860
Phase 3 - EAA171 Addition of Ixazomib to Lenalidomide in Patients With Residual Myeloma
2019 - (R) NCT03901963
Phase 3 - Dara + Len vs Len as Maint. in New Myeloma +MRD after frontline ASCT (AURIGA)
MGUS/SMM
2019 - (R) NCT03937635
Phase 3 - Lenalidomide, Dex +/- Daratumumab in High-Risk Smoldering Myeloma DETER-SMM
2018 - (R) NCT03689595
PROMISE Study - Predicting Progression of Developing MM in a High-Risk Screened Population
2017 - (R) NCT03289299
Phase 2 - Agg. Smoldering Curative Approach Eval. Novel Therapies & Transplant ASCENT
bottom of page